Akebia Therapeutics (STU:AX9) Cyclically Adjusted Book per Share: €1.63 (As of Mar. 2026)


STU:AX9 Akebia Therapeutics Inc STU:AX9
50 GF Score
Price €0.98
GF Value €1.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Akebia Therapeutics Cyclically Adjusted Book per Share?

Akebia Therapeutics STU:AX9 -0.35% 50 Cyclically Adjusted Book per Share is €1.63 as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 50/100 and a GF Value™ of €1.15 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Akebia Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €0.088. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Akebia Therapeutics's average Cyclically Adjusted Book Growth Rate was -22.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Akebia Therapeutics was -14.30% per year. The lowest was -14.30% per year. And the median was -14.30% per year.

As of today (2026-06-30), Akebia Therapeutics's current stock price is €0.9754. Akebia Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €1.63. Akebia Therapeutics's Cyclically Adjusted PB Ratio of today is 0.60.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Akebia Therapeutics was 1.70. The lowest was 0.08. And the median was 0.50.


Akebia Therapeutics  (STU:AX9) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Akebia Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.9754/1.63
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Akebia Therapeutics was 1.70. The lowest was 0.08. And the median was 0.50.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Akebia Therapeutics Cyclically Adjusted Book per Share Related Terms


Akebia Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Cyclically Adjusted Book per Share Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.55 3.04 2.49 1.67

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 1.98 1.79 1.67 1.63

STU:AX9 vs TKNO, ORGO, SIGA: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:AX9
50GF Score
Akebia Therapeutics Inc STU:AX9
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akebia Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.088/330.2130*330.2130
=0.088

Current CPI (Mar. 2026) = 330.2130.

Akebia Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.121 241.018 4.276
201609 2.346 241.428 3.209
201612 1.672 241.432 2.287
201703 0.737 243.801 0.998
201706 1.194 244.955 1.610
201709 1.774 246.819 2.373
201712 2.175 246.524 2.913
201803 2.811 249.554 3.720
201806 2.496 251.989 3.271
201809 2.141 252.439 2.801
201812 4.782 251.233 6.285
201903 4.280 254.202 5.560
201906 3.869 256.143 4.988
201909 3.572 256.759 4.594
201912 2.920 256.974 3.752
202003 2.754 258.115 3.523
202006 2.297 257.797 2.942
202009 1.883 260.280 2.389
202012 1.375 260.474 1.743
202103 1.133 264.877 1.412
202106 0.854 271.696 1.038
202109 0.668 274.310 0.804
202112 0.370 278.802 0.438
202203 0.129 287.504 0.148
202206 0.321 296.311 0.358
202209 0.076 296.808 0.085
202212 0.027 296.797 0.030
202303 -0.072 301.836 -0.079
202306 -0.132 305.109 -0.143
202309 -0.196 307.789 -0.210
202312 -0.144 306.746 -0.155
202403 -0.120 312.332 -0.127
202406 -0.149 314.175 -0.157
202409 -0.215 315.301 -0.225
202412 -0.209 315.605 -0.219
202503 0.087 319.799 0.090
202506 0.096 322.561 0.098
202509 0.134 324.800 0.136
202512 0.105 324.054 0.107
202603 0.088 330.213 0.088

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €1.63 mean?
Akebia Therapeutics (STU:AX9) has a Cyclically Adjusted Book per Share of €1.63 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Cyclically Adjusted Book per Share too high?
Akebia Therapeutics' current Cyclically Adjusted Book per Share is €1.63. Overall, Akebia Therapeutics has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Cyclically Adjusted Book per Share compare to TKNO and ORGO?
Akebia Therapeutics' Cyclically Adjusted Book per Share of €1.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Cyclically Adjusted Book per Share is €1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.15, compared to a current price of €0.98 — trading 15.2% below its estimated fair value. The current Cyclically Adjusted Book per Share is €1.63. Akebia Therapeutics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Cyclically Adjusted Book per Share is €1.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €0.98 is trading 15.2% below its estimated GF Value™ of €1.15. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AX9:

  • Cyclically Adjusted Book per Share: €1.63
  • GF Value™: €1.15 vs. price of €0.98 (15.2% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
50GF Score

Get the complete analysis for STU:AX9

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.98
Price
€1.15
GF Value